RxDoctor Payments Data

Evsen Alasyali, MD

Psychiatry · Columbus, OHNPI 1942389390

Payments from drug & device makers

$2,279in general payments, 2019–2025

Across 109 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$578
  • Johnson & Johnson$572
  • Neurocrine Biosciences, Inc.$252
  • Sunovion Pharmaceuticals Inc.$171
  • Axsome Therapeutics, Inc.$121
  • Vanda Pharmaceuticals Inc.$114
  • plus $470 from 9 others

What the payments were for

  • Food & beverage$2,279100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,279 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$26,176
Medicare patients
22
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$127,652
RexultiBrexpiprazole13$19,562
SeroquelQuetiapine Fumarate12$9,556
TrintellixVortioxetine Hydrobromide11$4,907
Aripiprazole43$4,627
Atomoxetine Hcl24$3,819
Divalproex Sodium ErDivalproex Sodium57$3,521
Ziprasidone Hcl36$3,190
Quetiapine Fumarate61$2,436
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine40$1,813
Vilazodone Hcl11$1,504
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,415
Risperidone69$1,307
LoxapineLoxapine Succinate21$1,183
Divalproex Sodium52$1,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$252$127,65215 claims
Otsuka America Pharmaceutical, Inc.Rexulti$578$19,56213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →